MedTrace Logo

Trial of Combination Therapy to Treat COVID-19 Infection

NCT04482686 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2024-09-24

No results posted yet for this study

Summary

In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.

Conditions

  • COVID
  • Covid-19
  • Corona Virus Infection
  • Coronavirus Infection
  • Coronavirus-19
  • SARS-CoV2
  • SARS-CoV Infection

Interventions

DRUG

Ivermectin

Treatment days 1, 4, and 8

DRUG

Doxycycline Hcl

10 day treatment

DIETARY_SUPPLEMENT

Zinc

10 Day treatment

DIETARY_SUPPLEMENT

Vitamin D3

10 day treatment

DIETARY_SUPPLEMENT

Vitamin C

10 day treatment

Sponsors & Collaborators

  • ProgenaBiome

    lead OTHER

Principal Investigators

  • Sabine Hazan, MD · ProgenaBiome

  • Thomas Borody, MD · Topelia Therpeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-09
Primary Completion
2022-05-15
Completion
2022-07-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04482686 on ClinicalTrials.gov